Surgical Management of Inherited Breast Cancer: Role of Breast-Conserving Surgery

Recent studies have demonstrated that hereditary breast cancer (BC) has a prevalence of 5-10% among all BC diagnoses. Nowadays, significant technological advances in the identification of an increasingly broad spectrum of genetic mutations allow for the discovery of an ever-growing number of inherit...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-07, Vol.14 (13), p.3245
Main Authors: Magnoni, Francesca, Sacchini, Virgilio, Veronesi, Paolo, Bianchi, Beatrice, Bottazzoli, Elisa, Tagliaferri, Valentina, Mazzotta, Erica, Castelnovo, Giulia, Deguidi, Giulia, Rossi, Elisabetta Maria Cristina, Corso, Giovanni
Format: Article
Language:English
Subjects:
BRCA1 protein
Breast cancer
Breast surgery
Family medical history
Mutation
Ovarian cancer
Patients
Point mutation
Review
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent studies have demonstrated that hereditary breast cancer (BC) has a prevalence of 5-10% among all BC diagnoses. Nowadays, significant technological advances in the identification of an increasingly broad spectrum of genetic mutations allow for the discovery of an ever-growing number of inherited pathogenic (P) or likely pathogenic (LP) variants of breast cancer susceptibility genes. As the management of BC patients carrying mutations in the genes or other high-penetrance genes is currently a challenge, extensive research is being carried out and a lively scientific debate has been taking place on what the most appropriate local therapy, especially surgical treatment, of patients with inherited BC should be. In many studies, BC outcomes in carriers and non-carriers have been compared. A number of them showed that, when compared with mastectomy, breast-conserving surgery in patients is oncologically safe in terms of overall survival, although an increased risk of ipsilateral recurrence was reported. In these patients, devising a specific therapeutic strategy is an inevitably complex process, as it must take into consideration a series of factors, require a multimodal approach, guarantee personalization, strictly adhere to scientific international guidelines, and consider all available evidence. The present narrative review purposes to identify and illustrate evidence from significant selected studies that discussed those issues, as well as to suggest useful tools to clinicians managing this specific clinical condition in daily clinical practice.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14133245